GE Medical Systems is trying to overturn an arbitration panel'sruling that the Milwaukee vendor owes Star Technologies $9.1 millionfor allegedly breaking a contract between the firms. Star, ofSterling, VA, had been supplying GE with CT reconstruction
GE Medical Systems is trying to overturn an arbitration panel'sruling that the Milwaukee vendor owes Star Technologies $9.1 millionfor allegedly breaking a contract between the firms. Star, ofSterling, VA, had been supplying GE with CT reconstruction processorsuntil early last year, when GE broke off the deal in favor ofits own processors. Star accused GE of using Star technology todevelop the new processors (SCAN 3/27/96).
GE filed a state court lawsuit in Delaware last month to overturnthe ruling, and; has also filed an appeal with the American ArbitrationAssociation, according to Brenda Potosnak, Star's controller andtreasurer. Star maintains that GE's avenues for appeal of theruling are limited. A GE representative declined to comment onthe dispute.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.